

August 14, 2025

The Manager – Listing

BSE Limited

1st Floor, New Trading Ring

Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the unaudited financial results for the quarter ended June 30, 2025.

Thanking you,

For AstraZeneca Pharma India Limited

Manasa. R

Company Secretary

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited Sustains Growth Momentum in Q1 FY25-26, Advancing Performance Across Diverse Therapies

Revenue rises **36%** in Q1 2025-26; four new approvals reinforce leadership in Oncology

Bengaluru, August 14, 2025: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its financial results for the quarter ended June 30, 2025. Demonstrating consistent growth across therapy areas, the Company reported a revenue increase of **36%** compared to the same period last year, supported by strategic execution, regulatory milestones, and continued portfolio expansion.

Financial performance Summary:

Summary		Q1 2025 Apr -Jun'25 (Value in INR Mn)	Q1 2024 Apr -Jun'24 (Value in INR Mn)
Total Revenue from Operation		5263.1	3,875.2
Profit before exceptional item and tax		750.6	424.0
Profit after exceptional item and tax		558.3	(117.9)
TA-wise performance	Oncology	3702.7	2,394.2
	Biopharmaceuticals (CVRM, R&I and V&I)	1183.2	1,263.3
	Rare Disease	4.2	2.1

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, “Our strong Q1 performance reflects the power of science-led innovation combined with disciplined execution. Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most.”

Praveen Rao Akkinipally, Country President & Managing Director, said, “Delivering consistent growth across therapy areas reaffirms the strength of our Growth Through Innovation strategy and the passion of our teams to help more patients. At AstraZeneca, we are guided by a bold ambition to transform patient outcomes by delivering the right treatment at the right time. These results are a testament to what is possible when science, and purpose come together.”

Key milestones:

- Received Central Drugs Standard Control Organisation (CDSCO) approval to import for sale and for distribution of Osimertinib tablets for an additional indication in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
- Received CDSCO approval to import for sale and for distribution of trastuzumab deruxtecan for additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients, who have received at least one endocrine therapy in metastatic setting.
- Gained CDSCO approval for additional indication of Osimertinib as a monotherapy, for import for sale and for distribution for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum based chemoradiation therapy.
- Through the CDSCO approval received for import for sale and for distribution of Benralizumab, it was for additional indication as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Recognitions:

- OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials.
- 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials.
- Featured by Fortune India as a leading multinational transforming healthcare in India.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: <https://www.astrazeneca.in/> or follow us on LinkedIn: [AstraZeneca India](#).